Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
نویسندگان
چکیده
منابع مشابه
Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
The radioprotective agent WR-2721 was examined for its effects on modifying the cytotoxicity of HN2 against normal and tumor cells in the AKR mouse. Quantitation was carried out by the spleen colony assay for both normal hematopoietic stem cells and AKR leukemia cells. Protection from drug toxicity and normal cell cytotoxicity was noted. Potentiation of cytotoxicity to AKR leukemia was found.
متن کاملDerivatives: Form of the Drug Responsible for Protection Radioprotection of Cells in Culture by WR-2721 and Updated Version
Studies of V79-171 cells were undertaken to determine what extracel lular or intracellular derivative of the drug WR-2721 is associated with radioprotection. The effect of preincubation at 23 ±1°Cwith WR-2721, and with derivatives of WR-2721 produced in medium containing alkaline phosphatase, upon survival of cells following subsequent -y-irradiation was examined. It was established that WR-2...
متن کاملCisplatin nephrotoxicity and protection by silibinin.
BACKGROUND The anticancer drug cisplatin is know to have toxic side-effects on different segments of the nephron. The flavonoid silibinin has previously been shown to be protective in models of hepatotoxicity. The aim of the present study was to evaluate, whether silibinin can also ameliorate alterations in renal glomerular and tubular function and tubular morphology induced by cisplatin. MET...
متن کاملEffects of ethiofos (WR-2721) and radiation on monkey visual discrimination performance.
WR-2721 (ethiofos) is a promising protector against radiation-induced lethality and may be useful in cancer radiotherapy (Davidson et al . , 1980). However, ethiofos also produces nausea, vomiting, diarrhea, and hypotension, which implies severe behavioral consequences (Bogo et al . , 1985). We studied the effects of ethiofos on behavior in monkeys and its ability to mitigate early transient in...
متن کاملA phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Melphalan has a steep dose-response curve, but the use of high doses results in unacceptable myelosuppression. Strategies to circumvent this dose-limiting myelosuppression would allow for the administration of higher, more effective doses of melphalan. Amifostine (WR-2721) has been shown in preclinical studies to protect the bone marrow from the myelotoxicity of melphalan, and in clinical trial...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1988
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a